GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (STU:0NN) » Definitions » Other Operating Expense

Avicanna (STU:0NN) Other Operating Expense : €0.90 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Avicanna Other Operating Expense?

Avicanna's Other Operating Expense for the three months ended in Dec. 2024 was €0.27 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.90 Mil.

Avicanna's quarterly Other Operating Expense declined from Jun. 2024 (€0.24 Mil) to Sep. 2024 (€0.21 Mil) but then increased from Sep. 2024 (€0.21 Mil) to Dec. 2024 (€0.27 Mil).

Avicanna's annual Other Operating Expense declined from Dec. 2022 (€0.88 Mil) to Dec. 2023 (€0.83 Mil) but then increased from Dec. 2023 (€0.83 Mil) to Dec. 2024 (€0.90 Mil).


Avicanna Other Operating Expense Historical Data

The historical data trend for Avicanna's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna Other Operating Expense Chart

Avicanna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only 1.16 0.73 0.88 0.83 0.90

Avicanna Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.18 0.24 0.21 0.27

Avicanna Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avicanna Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Avicanna's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Avicanna Business Description

Traded in Other Exchanges
Address
480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Avicanna Headlines

No Headlines